Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Tuberculosis DNA vaccine Ag85A (Primary) ; Tuberculosis DNA vaccine Ag85A
- Indications Tuberculosis
- Focus Adverse reactions
- 06 Sep 2017 Status changed from not yet recruiting to recruiting.
- 29 May 2017 Planned primary completion date changed from 30 Apr 2017 to 31 Dec 2019.
- 29 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.